Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

12

Revenue 2014

Amgen

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Amgen's 2013 sales performance.

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita

Amgen wins European approval for Humira biosimilar Amgevita. European Commission approves the first version of AbbVie's blockbuster. ... Meanwhile, in Europe Amgen’s new product has a duplicate marketing authorisation under the brand name Solymbic.

HTA guidance from NICE, the SMC and the AWMSG

8 Mar 2017. Draft guidance recommends Amgen treatment for secondary hyperparathyroidism.

A new decade of disruption: meeting the biosimilar challgenge

A new decade of disruption: meeting the biosimilar challgenge Building strategic advantage. At a broader level, many of the larger biotech and pharma companies, such as Amgen, Biogen, Boehringer Ingelheim, Novartis and Pfizer, have taken the strategic decision to develop

Repatha outcomes data "less than stellar"

Repatha outcomes data "less than stellar" Repatha outcomes data "less than stellar". Analysts underwhelmed by latest results on Amgen's drug despite it seeing some improvements. ... The steep price differential means that around two-thirds of patients are unable to receive insurance coverage for

Mylan deal with Roche clears path to biosimilar Herceptin launch

Mylan deal with Roche clears path to biosimilar Herceptin launch of fighting their patent infringement battle, although there are other biosimilar Herceptin developers waiting in the wings, including Amgen/Allergan, Pfizer, and Samsung Bioepsis.

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's premier medical animation company. Over the past 20 years we have created over 350 mechanism-of-action (MoA)...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics